The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells. - Test2 - elhamkhani - TriplyDB

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

http://www.wikidata.org/entity/Q39195579

about

Small-molecule SMAC mimetics as new cancer therapeutics Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy Targeting Non-proteolytic Protein Ubiquitination for the Treatment of Diffuse Large B Cell Lymphoma Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs)Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.Discovery of novel second mitochondria-derived activator of caspase mimetics as selective inhibitor of apoptosis protein inhibitors.Eliminating hepatitis B by antagonizing cellular inhibitors of apoptosis.Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.Diffusion-weighted MRI for imaging cell death after cytotoxic or apoptosis-inducing therapy.USP11-dependent selective cIAP2 deubiquitylation and stabilization determine sensitivity to Smac mimetics.An apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.IAP antagonists Birinapant and AT-406 efficiently synergise with either TRAIL, BRAF, or BCL-2 inhibitors to sensitise BRAFV600E colorectal tumour cells to apoptosis.PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition Molecular pathways: turning proteasomal protein degradation into a unique treatment approach.Pharmacodynamic markers and clinical results from the phase 2 study of the SMAC mimetic birinapant in women with relapsed platinum-resistant or -refractory epithelial ovarian cancer.Effect of a Smac Mimetic (TL32711, Birinapant) on the Apoptotic Program and Apoptosis Biomarkers Examined with Validated Multiplex Immunoassays Fit for Clinical Use.Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein antagonist birinapant APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.Smac-mimetic-induced epithelial cell death reduces the growth of renal cysts.Inhibitor of Apoptosis Proteins (IAPs) are commonly dysregulated in GIST and can be pharmacologically targeted to enhance the pro-apoptotic activity of imatinib Receptor-interacting protein 1 increases chemoresistance by maintaining inhibitor of apoptosis protein levels and reducing reactive oxygen species through a microRNA-146a-mediated catalase pathway.Analysis of the inhibitors of apoptosis identifies BIRC3 as a facilitator of malignant progression in glioma.Targeting Programmed Cell Death Using Small-Molecule Compounds to Improve Potential Cancer Therapy.Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms.Selective replication of oncolytic virus M1 results in a bystander killing effect that is potentiated by Smac mimetics.IAP antagonization promotes inflammatory destruction of vascular endothelium.Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant.Negative correlation between X-linked inhibitors of apoptosis and second mitochondria-derived activator of caspase expression levels in cervical carcinoma and cervical intraepithelial neoplasia.Targeting inhibitor of apoptosis proteins by Smac mimetic elicits cell death in poor prognostic subgroups of chronic lymphocytic leukemia.Targeting the intrinsic apoptosis pathway as a strategy for melanoma therapy.Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.Simulating and predicting cellular and in vivo responses of colon cancer to combined treatment with chemotherapy and IAP antagonist Birinapant/TL32711.Interferon-γ and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFα-independent manner.Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection Differentiated macrophages acquire a pro-inflammatory and cell death-resistant phenotype due to increasing XIAP and p38-mediated inhibition of RipK1

P2860

Q26864204-E2ACB23B-2B03-4D6A-923D-87AAA6CED470 Q26993238-9A0849DE-9F19-4BDE-9F58-56B32871B87E Q28115962-C903F6FC-E740-4A14-878D-D755E4F64B96 Q33841579-059DE3AD-0F5D-4C8E-8291-BCFCFB385227 Q33897223-22D2B7C4-061F-4983-A97B-8948E949CBCF Q35119355-90A46539-FA74-496C-B6D7-C518E10270A0 Q35590251-615CD1C0-BB98-4927-A068-25E1398A0BD0 Q35600313-4A6F4D36-EBBF-44BD-9D8E-7AE2250769A6 Q35677936-6C26F4A1-37B0-4F60-9023-37039D08DC67 Q35941474-2E1A176F-022B-402B-9AD7-4F90FAC26DFD Q35941858-A66E5E31-5A60-4115-B43F-656493BA3435 Q36103378-43292EF3-527E-44AD-A5FD-F52B5098FF85 Q36215920-2F1612AA-47B8-4228-8815-826ADD1D1B3A Q36436413-07D6B2D6-917C-4074-9408-344D6B46D976 Q36547383-A7C48348-17EC-472B-99E7-60A6344CC46D Q36586167-FF6231F5-38C7-4472-9DC8-B6C0DC7975C0 Q36750717-BC9657D7-758A-4925-BA9A-1FB794DDA741 Q37035836-A2E8F4F8-A2D3-483C-9247-BFF965C951A3 Q37340219-F626C153-97FF-458C-ABC6-505ABBCACBB4 Q37520240-83372E96-3D95-4C67-A01F-BC02AF75A913 Q37608457-86786E73-2067-44D3-BF61-E67065FABB47 Q37706475-14674E5C-5D3C-4BFE-948E-7F222A28DEAF Q38881119-DB55ECF1-8AF1-4CAD-8148-FF85C841B244 Q40071126-D0F10B26-9752-4CE2-AAD8-B05BBDC6C6D8 Q40162604-04B0895E-9F44-434D-A5E7-2A8542874A41 Q41889509-3504AB38-5829-4430-9ED3-C196ED91BCD8 Q42226188-99083B6C-B825-46B7-8B72-A18A68313957 Q45684338-4415D79B-6434-47AC-BAC1-3454A160342E Q46711978-94E00F7B-9FA7-414D-AA8A-335FE69621A6 Q51746852-CFABFF0B-D05C-4991-9158-718175446261 Q52571240-0B608854-B396-4361-B6A5-9F375CB1E1EB Q52676377-91DAE0E4-B452-421F-8158-B7E0D6FB16E5 Q55339903-7EECD001-C3EA-4643-9541-04A3815D120E Q57072848-06611D06-C603-40FD-86C5-C541F37CF554 Q57663667-CB815CCE-1799-418A-ABF4-42ECDD6A73DE

P2860

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

http://www.wikidata.org/entity/Q39195579

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

@en

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

@nl

type

label

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

@en

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

@nl

prefLabel

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

@en

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

@nl

P1433

Q39195579-05351AF2-3DAE-4865-AAE5-F394EB430A7A

P1476

Q39195579-2E82F595-67CA-43E4-9122-585126CD55FA

P2093

Q39195579-1BA22852-FF49-4ACB-868E-BCB30F57DCC1

Q39195579-49346037-5D1C-44F9-89E0-29A7ECED9A11

Q39195579-544D38C2-8417-4E91-B50B-FBF1D5A7C138

Q39195579-7D2EB326-9D2D-4C99-9F37-B8AA25CC76C3

Q39195579-860F5CB0-6940-40EF-B51A-6150220DA5B5

Q39195579-8803002D-E50B-4A46-B9BC-4890B213E8FC

Q39195579-94C5DE70-F053-4BBB-B4E4-5BFCF1D5C4FF

Q39195579-97011BD8-9490-4076-8E99-F08B5AF15EA0

Q39195579-9B1241EE-5D6F-4EF6-B8E8-D3B2E0EB10C2

Q39195579-A2444432-7DCF-43E8-AE0F-CEBA5CE405F0

P2860

Q39195579-05345A64-369E-4DAF-9876-43D55AD2CB2C

Q39195579-0FCDE87E-1208-455B-B8D3-7164E6247DD4

Q39195579-1038CEDC-2B28-4AEE-8533-83FC684C7EE5

Q39195579-126C3CAA-0CE5-43F4-96CA-50D06D591B02

Q39195579-13438247-E8A4-4EF7-82B4-543A9EDD6A6A

Q39195579-171AB5FB-BA62-4756-8867-B252B046756B

Q39195579-27EA211C-D1C0-4CEA-855D-98F26B9207D4

Q39195579-34F51088-03FE-4B8C-89D7-9918904E5416

Q39195579-3561980C-96EA-4BFF-A172-A00C7E04D794

Q39195579-36815C48-2380-4470-A22A-45EE4D14D2B8

P304

Q39195579-365E7D9B-B6B7-40AA-A101-F6DB803EDF05

P31

Q39195579-DA4D2CE7-4DC3-44D7-B63A-37B1A7A9639D

P356

Q39195579-F07CF6F6-9CC5-4829-B21D-35275822C64F

P407

Q39195579-FC599F48-51C6-47F3-82D8-0FE724D6692F

P433

Q39195579-8BECE664-0C67-4D7E-BA5E-6405308AB2EA

P478

Q39195579-E57C74FA-440D-4A9B-9232-7CBFD7667EBE

P50

Q39195579-65F21B85-5485-4451-A166-F8FDA6695DCC

Q39195579-6D027473-2EF1-4862-BF1F-96A96BACA1BC

Q39195579-7CED866C-8A4F-4545-A9DF-2E20DED428E6

Q39195579-D8B45099-3404-4048-A7B5-8A443CEADCE2

P577

Q39195579-3645A9B4-068A-4AEF-9B55-1981EA4DA16F

P5875

Q39195579-73D0B57D-624D-4141-AE04-0B9EFA6459B1

P698

Q39195579-FFC3A8A2-28F6-4148-8AB5-1C27BB2CEE00

P932

Q39195579-B9F00D4B-CAD2-4B45-92DD-8B113F19DD75

P356

1078-0432.CCR-12-2518

P1433

Clinical Cancer Research

P1476

The novel SMAC mimetic birinapant exhibits potent activity against human melanoma cells.

@en

P2093

Christopher Benetatos

http://www.w3.org/2001/XMLSchema#string

Eric M Neiman

http://www.w3.org/2001/XMLSchema#string

Hubert Pehamberger

http://www.w3.org/2001/XMLSchema#string

Jessie Villanueva

http://www.w3.org/2001/XMLSchema#string

Mark McKinlay

http://www.w3.org/2001/XMLSchema#string

Min Xiao

http://www.w3.org/2001/XMLSchema#string

Molly B Halloran

http://www.w3.org/2001/XMLSchema#string

Ravi K Amaravadi

http://www.w3.org/2001/XMLSchema#string

Srinivas K Chunduru

http://www.w3.org/2001/XMLSchema#string

Xu He

http://www.w3.org/2001/XMLSchema#string

P2860

IAPs: from caspase inhibitors to modulators of NF-kappaB, inflammation and cancer

Smac mimetic bypasses apoptosis resistance in FADD- or caspase-8-deficient cells by priming for tumor necrosis factor α-induced necroptosis

IAPs regulate the plasticity of cell migration by directly targeting Rac1 for degradation

IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis

IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis

Induction of TNF receptor I-mediated apoptosis via two sequential signaling complexes

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Inflammation and cancer

Melanoma: new insights and new therapies

P304

1784-1794

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-12-2518

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Meenhard Herlyn

Katherine L Nathanson

Clemens Krepler

P577

2013-02-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235603897

http://www.w3.org/2001/XMLSchema#string

P698

23403634

http://www.w3.org/2001/XMLSchema#string

P932

3618495

http://www.w3.org/2001/XMLSchema#string